Kymab Appoints Anne Hyland As Chief Financial Officer

Cambridge, UK, 19 February 2015: Kymab, a leader in the discovery and development of human therapeutic monoclonal antibodies generated using its unique discovery platform, announced today the appointment of Anne Hyland as Chief Financial Officer of Kymab, to take effect from 1 March 2015.

Anne has a strong track record within the biopharma sector, bringing with her over 25 years of financial experience with both public and private companies. Most recently, Anne served as Chief Financial Officer of BBI Diagnostics Group Ltd and FTSE listed Vectura Group plc (LSE: VEC). She currently serves as Non-executive Director and Chair of the Audit Committee of the FTSE-250 global specialty chemicals company, Elementis plc (LSE:ELM). Prior to Vectura, Anne held a number of senior finance position, including Director of Corporate Finance at the then FTSE 100 Celltech Group plc, Medeva plc and KPMG.

Dr David Chiswell, Chairman and interim CEO of Kymab. "I am very pleased to welcome Anne to Kymab's senior management team. Anne is an experienced CFO with a successful track record of creating value and growth for both public and private companies. Anne's strong skill set will be invaluable as we build Kymab into a substantial global biopharmaceutical company."

Newly appointed Chief Financial Officer Anne Hyland said: "I am delighted to join Kymab at this exciting time. The significant level of investment the company and management team has attracted is impressive. Kymab is a company with tremendous capabilities and talented people and I look forward to helping build further growth and value."

Anne is a Chartered Accountant (FCA), a Corporate Tax Adviser (CTA – AITI) and holds a degree in Business studies from Trinity College, Dublin. She is also a Trustee/Director of Sustrans, the charity that has created the National Cycle Network. Anne has been one of the Cranfield University Female FTSE 100 Women to Watch since 2009.


About Kymab

Kymab is a biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary Kymouse antibody platform.

Kymouse has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding that rare drug candidate with best-in-class characteristics. Kymab is using the platform for its internal drug discovery programmes and in partnership with pharmaceutical companies. The first Kymouse partnership agreement was concluded with Novo Nordisk in 2013.

Founded in 2009, Kymab has raised over $70m of equity financing from the Wellcome Trust and the Bill & Melinda Gates Foundation. It has an experienced management team with a successful track record in drug discovery and development and has 12 current therapeutic antibody discovery programmes in immune-oncology, auto-immunity, haematology, chronic pain, dyslipidaemia and cardiovascular diseases.

Kymab, Kymouse, Kymab Access are trademarks of Kymab Limited.

For further information contact:

Hume Brophy
Mary Clark, Hollie Vile
Tel: +44 (0)20 3440 5653, Email: [email protected]


Anne Hyland
Tel: + 44 7841278537, Email: [email protected]

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.